Additional Guidance on the Use of the PRESERFLOTM MicroShunt in the Treatment of Glaucoma: Insights from a Second Delphi Consensus Panel

Anthony P. Khawaja,Luís Abegão Pinto,Ingeborg Stalmans,Florent Aptel,Anna Barkander,Keith Barton,Henny Beckers,Milko Iliev,Thomas Klink,Giorgio Marchini,Jose Martínez de la Casa,Karin R. Pillunat,Jan H. Simonsen,Clemens Vass
DOI: https://doi.org/10.1007/s40123-024-00902-5
2024-04-09
Ophthalmology and Therapy
Abstract:The PRESERFLOTM MicroShunt (PMS) has been proven to significantly lower intraocular pressure (IOP) in patients with glaucoma and has been available for use since 2019. With increasing published evidence and growing experience of glaucoma surgeons, the aim of this modified Delphi panel was to build on the findings of a previous Delphi panel conducted in 2021 and provide further guidance on the role of the PMS to treat patients with glaucoma in Europe.
ophthalmology
What problem does this paper attempt to address?